Skip to main content
. Author manuscript; available in PMC: 2016 Oct 15.
Published in final edited form as: Biochem Pharmacol. 2015 Jul 23;97(4):488–497. doi: 10.1016/j.bcp.2015.07.019

Figure 4.

Figure 4

Single-housed male C57BL/6 mice were pretreated with the heteromeric nAChR antagonist dihydro-β-erythroidine (DHβE, 3 mg/kg) (A–C) or the homomeric nAChR antagonist methyllycaconitine (MLA, 5 mg/kg) (D–F) 15 minutes prior to injection with nicotine (0.25 mg/kg) or vehicle. Control groups were pretreated with vehicle followed by treatment with vehicle or nicotine. Percentage of attacking mice (A, D), latency to attack (B, E), and total number of attacks (C, F) were recorded; between-subjects testing: N = 14 for vehicle/vehicle, vehicle/nicotine, DHβE/vehicle; N = 13 for DHβE/nicotine; N = 17 for MLA/vehicle and MLA/nicotine. Note the vehicle/vehicle and vehicle/nicotine data shown in A-C and D-F are from one experiment that is duplicated for comparison to both antagonist groups. Home cage distance traveled was recorded 10 minutes after pretreatment with either vehicle or DHβE followed by treatment with either vehicle or nicotine (0.25 mg/kg) (G); between-subjects testing: N = 5 per treatment condition. Error bars represent S.E.M. *P < 0.05. #P = 0.06 vs. respective vehicle-treated group; ns, not significant.